FCH
Positron Emission Tomography
National Taiwan University HospitalSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Positron Emission Tomography cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
GADOPENTETATE DIMEGLUMINE National Taiwan University Hospital | Phase 4 | B |
Psma-Hbed-Cc Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | B |
DOTA-FAPI-04 GALLIUM GA-68 First Affiliated Hospital of Fujian Medical University | Early Phase 1 | C |
FLUDEOXYGLUCOSE University of California, Davis | Early Phase 1 | C |
DPA-714 University of California, Davis | Early Phase 1 | C |
CIMBI-36 University of Exeter | D | |
DASB University of Exeter | D |
Same molecule, other indications
FCH is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →